Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.42 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.39 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL435597 | 0.95 | DPP4 (0.43) | OPRM1OPRK1CYP2D6OPRD1ACKR3 | |
| SCHEMBL434260 | 0.91 | OPRK1 (0.52) | OPRM1OPRK1CYP2D6OPRD1 | |
| SCHEMBL433988 | 0.91 | OPRK1 (0.52) | OPRM1OPRK1CYP2D6OPRD1 | |
| SCHEMBL433020 | 0.89 | OPRM1 (0.42) | OPRM1OPRK1CYP2D6OPRD1ACKR3 | |
| SCHEMBL433697 | 0.89 | OPRK1 (0.44) | OPRM1OPRK1CYP2D6OPRD1ACKR3 | |
| SCHEMBL15380176 | 0.89 | OPRM1 (0.42) | OPRM1OPRK1CYP2D6OPRD1ACKR3 | |
| SCHEMBL15380174 | 0.89 | OPRM1 (0.42) | OPRM1OPRK1CYP2D6OPRD1ACKR3 | |
| SCHEMBL10083993 | 0.87 | OPRK1 (0.47) | OPRM1OPRK1CYP2D6OPRD1KCNK3 | |
| SCHEMBL435629 | 0.87 | OPRK1 (0.47) | OPRM1OPRK1CYP2D6OPRD1KCNK3 | |
| SCHEMBL15385506 | 0.84 | CCR5 (0.45) | OPRM1OPRK1CYP2D6OPRD1ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9303027-B2 | Kappa opioid receptor agonists | DR. REDDY'S LABORATORIES LTD. (IN) | 2016-04-05 | — | — | US | disclosed |
| US-9303027-B2 | Kappa opioid receptor agonists | DR. REDDY'S LABORATORIES LTD. (IN) | 2016-04-05 | — | — | US | disclosed |
| US-20130303525-A1 | KAPPA OPIOID RECEPTOR AGONISTS | DR. REDDY'S LABORATORIES, INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130303525-A1 | KAPPA OPIOID RECEPTOR AGONISTS | DR. REDDY'S LABORATORIES, INC. (US) | 2013-11-14 | — | — | US | disclosed |
| WO-2012012410-A2 | KAPPA OPIOID RECEPTOR AGONISTS | DR. REDDY'S LABORATORIES LTD. (IN) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303525-A1 | KAPPA OPIOID RECEPTOR AGONISTS | OPRK1, OPRL1, OPRD1 | OPRM1 4/4885OPRK1 1/4885CYP2D6 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.